Tonix doses first patient in Phase 2 OASIS trial of TNX-102 SL for acute stress reaction

Tonix Pharmaceuticals Holding Corp.

• Phase 2 OASIS trial evaluating TNX-102 SL in reducing severity of acute stress reaction and frequency of acute stress disorder.
• Trial sponsored by UNC Institute for Trauma Recovery with a $3 million grant from the U.S. Department of Defense.
• Plans to enroll ~180 motor vehicle collision survivors at U.S. emergency departments; randomized to TNX-102 SL 5.6 mg or placebo for two weeks.
• Topline results expected in the second half of 2026.